CHLORPROMAZINE

First approved in 1954

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN(C)CCCN1C2=C(SC3=C1C=C(Cl)C=C3)C=CC=C2

InChI

InChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N

InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3

HIDE SMILES / InChI

Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/chlorpromazine.html | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display | https://www.drugbank.ca/drugs/DB00477

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 290 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16867246 \| https://www.ncbi.nlm.nih.gov/pubmed/25557493 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2737	1.0 nM [IC50]
Serotonin 2a (5-HT2a) receptor 229 Target ID: CHEMBL224 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2737	3.4 nM [IC50]
Dopamine D1 receptor 98 Target ID: CHEMBL2056 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2737	56.0 nM [Ki]
Histamine H1 receptor 312 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2737	12.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 288 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8307	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date -3.82319985E11
Manic-depressive disease 9 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8307	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date -3.82319985E11
Acute intermittent porphyria 7 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8307	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date -3.82319985E11
Nausea and vomiting 19 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8307	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date -3.82319985E11

C_max

Value	Dose	Analyte	Population
37.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.31 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
135 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
11.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4399487	unknown, unknown		CHLORPROMAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
75 mg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	unhealthy, 52 years (range: 36.5-65.6 years) Health Status: unhealthy Condition: agitation Age Group: 52 years (range: 36.5-65.6 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	Sources: https://pubmed.ncbi.nlm.nih.gov/30558470
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

AEs

AE	Significance	Dose	Population
Adverse event	grade 5	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
Adverse event	grade 5	25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1670		inhibitor 1789 substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2E1 846 P-gp 1401 BCRP 678 UGT2B10 25 OCT2 630 OATP1A2 34	CYP1A2 1013 P-gp 1491	CYP2B 32 CYP3A 125

Drug as perpetrator

Target	Modality	Activity
BCRP 751	inhibitor 3185 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637613/	mild [IC50 52.2 uM]
CYP2E1 929	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/15135088/	weak [IC50 1000 uM]
OATP1A2 34	inhibitor 3185 Sources: https://jpet.aspetjournals.org/content/352/3/552?cited-by=yes&legid=jpet%3B352/3/552	yes [IC50 12 uM]
OCT2 631	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 14 uM]
CYP2D6 1826	inhibitor 3185 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 20 uM]
P-gp 1588	inhibitor 3185 Sources: https://link.springer.com/article/10.1007/s00213-006-0437-9?shared-article-renderer	yes [IC50 5.8 uM]
UGT2B10 27	inhibitor 3185 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/378.full.pdf#page=6 Page: 6.0	yes [IC50 79 uM]
CYP1A2 1620	inhibitor 3185 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 9.5 uM]
CYP2B 40	inducer 1515 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes
CYP3A 291	inducer 1515 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1013	substrate 3264 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
CYP2D6 1168	substrate 3264 Sources: https://www.sciencedirect.com/science/article/pii/S1110863017300228	yes
CYP3A4 1670	substrate 3264 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
P-gp 1491	substrate 3264 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913737/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573882/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3647	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3647
ChemicalBook	CB5547531	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5547531
MolPort	MolPort-001-727-953	https://www.molport.com/shop/molecule-link/MolPort-001-727-953
ZINC	ZINC000000044027	http://zinc15.docking.org/substances/ZINC000000044027
eMolecules	730270	https://www.emolecules.com/cgi-bin/more?vid=730270

PubMed

Title	Date	PubMed
Deanol in the treatment of tardive dyskinesia.	1975 Aug	1147074
Drug-induced dystonia.	1975 May	1119613
Effects of chlorpromazine on bilirubin metabolism and biliary secretion in the rat.	1975 Oct	1175890
Altered pilocarpine- or chlorpromazine-induced catalepsy after long-term treatment with cholinergic drugs.	1979 Nov	119254
A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.	1992	1509179
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.	1992	1350058
Chlorpromazine: a drug potentially useful for treating mycobacterial infections.	1992	1288966
An unusual cause of convulsions in a newborn infant.	1992 Dec	1473547
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.	1992 Jul	1353247
The use of a side effect as a qualitative indicator of plasma chlorpromazine levels.	1999 Jan	10082231
Tardive dystonia induced by risperidone.	1999 Jun	10389620
Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans.	2000 Sep	10952582
Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts.	2001 Jul	11515722
Combination of benzo[a]phenothiazines with acyclovir against herpes simplex virus.	2001 Jul	11463529
Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.	2001 Jul	11444585
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.	2001 Mar	11282269
Bipolar disorder after mefloquine treatment.	2001 May	11394195
Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.	2001 May	11328759
Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response.	2002	12049174
[Creutzfeldt-Jakob disease: diagnosis, incidence, prevention and treatment].	2002 Apr 20	11998351
Effects of chlorpromazine, pentoxifylline and dexamethasone on mRNA expression of lipopolysaccharide-induced inflammatory cytokines in bovine peripheral blood mononuclear cells.	2002 Aug	12237520
[Models of drug treatment in the attention deficit disorder with hyperactivity].	2002 Feb	12447798
Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.	2002 May	12010767
Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.	2002 Nov-Dec	12512871
Dual action of oestrogens on the mouse constitutive androstane receptor.	2003 Dec 1	12948398
Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines.	2003 Jan	12520151
QTc prolongation: chlorpromazine and high-dosage olanzapine.	2003 Jun	12866343
Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123.	2003 Jun	12626638
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.	2003 Mar	12604522
Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1.	2003 Mar 14	12501239
New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.	2003 May 10	12747876
Sydenham's chorea may be a risk factor for drug induced parkinsonism.	2003 Sep	12933958
[Differences in prooxidant effect of neuroleptics haloperidol and aminazine].	2003 Sep-Oct	14650217
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.	2004 Apr	15052360
Drug-induced liver injury.	2004 Mar 1	14986274
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.	2004 May	15071359
Oral terbutaline in the management of pharmacologically induced prolonged erection.	2004 Oct	14999218
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.	2005 Nov	16251329
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.	2006 Apr 15	16294319
Frequency of high-risk use of QT-prolonging medications.	2006 Jun	16178046

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day

Route of Administration: Other

In Vitro Use Guide

Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 16 16:36:58 UTC 2022` Edited by `admin` on `Fri Dec 16 16:36:58 UTC 2022`
Record UNII	U42B7VYA4P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORPROMAZINE

Official Name

English

CHLORPROMAZINUM

Common Name

English

ESMIND

Common Name

English

CHLORPROMAZINE [MART.]

Common Name

English

2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine

Systematic Name

English

CHLORPROMAZINUM [HPUS]

Common Name

English

Chlorpromazine [WHO-DD]

Common Name

English

NSC-226514

Code

English

SANOPRON

Common Name

English

CHLORPROMAZINE [VANDF]

Common Name

English

chlorpromazine [INN]

Common Name

English

J2.794D

Code

English

SKF-2601A

Code

English

CHLORPROMAZINE [HSDB]

Common Name

English

CHLORPROMAZINE [USP MONOGRAPH]

Common Name

English

NSC-167745

Code

English

PROPAPHENIN

Common Name

English

10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-

Systematic Name

English

CPZ

Common Name

English

3-(2-CHLORO-10H-PHENOTHIAZIN-10-YL)-N,N-DIMETHYLPROPAN-1-AMINE

Systematic Name

English

LARGACTILOTHIAZINE

Common Name

English

WINTERMIN

Common Name

English

FENACTIL

Common Name

English

CHLORPROMAZINE [ORANGE BOOK]

Common Name

English

THORAZINE

Brand Name

English

NOVOMAZINA

Common Name

English

CHLORPROMAZINE [MI]

Common Name

English

AMINAZINE

Common Name

English

Classification Tree Code System Code

WHO-ATC

N05AA01